levothyroxine sodium · Ibsa · NDA 021924
Tirosint
Earliest generic entry, as listed · earliest of 15 marketed strengths
26 Sep 2044
Blocked by patent: US 12564565.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12564565 | drug product · sets the listed date | 26 Sep 2044 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 15
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021924 · 002 · RLD | capsule, oral | 0.025MG | 26 Sep 2044 |
| 021924 · 003 · RLD | capsule, oral | 0.05MG | 26 Sep 2044 |
| 021924 · 004 · RLD | capsule, oral | 0.075MG | 26 Sep 2044 |
| 021924 · 005 · RLD | capsule, oral | 0.1MG | 26 Sep 2044 |
| 021924 · 006 · RLD | capsule, oral | 0.125MG | 26 Sep 2044 |
| 021924 · 007 · RLD | capsule, oral | 0.15MG | 26 Sep 2044 |
| 021924 · 008 · RLD | capsule, oral | 0.112MG | 26 Sep 2044 |
| 021924 · 009 · RLD | capsule, oral | 0.137MG | 26 Sep 2044 |
| 021924 · 010 · RLD | capsule, oral | 0.088MG | 26 Sep 2044 |
| 021924 · 011 · RLD | capsule, oral | 0.175MG | 26 Sep 2044 |
| 021924 · 012 · RLD | capsule, oral | 0.2MG | 26 Sep 2044 |
| 021924 · 013 · RLD | capsule, oral | 0.013MG | 26 Sep 2044 |
| 021924 · 014 · RLD | capsule, oral | 0.0375MG | 26 Sep 2044 |
| 021924 · 015 · RLD | capsule, oral | 0.044MG | 26 Sep 2044 |
| 021924 · 016 · RLD | capsule, oral | 0.0625MG | 26 Sep 2044 |